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Abstract 24 
Atazanavir is an HIV-1 protease inhibitor (PI) with high protein binding in human plasma. The 25 
objectives were first to determine the in vitro binding characteristics of atazanavir, second to 26 
evaluate whether plasma protein binding to albumin and to orosomucoid (alpha 1 glycoprotein 27 
acid) influence the pharmacokinetics of atazanavir in HIV-infected patients. For the in vitro 28 
study, atazanavir protein binding characteristics were determined in alpha 1 glycoprotein acid and 29 
albumin purified solutions. Atazanavir was found to bind alpha 1 glycoprotein acid on a high 30 
affinity saturable site (association constant 4.61 10
5
 L/mol) and albumin on a low-affinity non-31 
saturable site. For the in vivo study, blood samples from 51 patients included in the ANRS107–32 
Puzzle 2 trial were drawn prior to drug intake at week 6. For 10 patients included in the 33 
pharmacokinetic substudy, five additional blood samples were collected during one dosing 34 
interval at week 6. Atazanavir concentrations were assayed by LC-MS/MS. Albumin 35 
concentrations, alpha 1 glycoprotein acid concentrations and phenotypes were also measured in 36 
these patients. Concentrations of atazanavir were modelled using a population approach. A one-37 
compartment model with first-order absorption and elimination best described atazanavir 38 
pharmacokinetics. Atazanavir pharmacokinetic parameters and their interindividual variabilities 39 
(%) were as follows: absorption rate constant (ka) 0.73 h
-1
 (139.3%), apparent clearance (Cl/F) 40 
13.3 L/h (26.7%) and apparent volume of distribution (V/F) 79.7 L (27.0%). Atazanavir Cl/F 41 
decreased significantly when alanine aminotransferase and/or alpha 1 glycoprotein acid levels 42 
increased (p<0.01). ORM1*S alpha 1 glycoprotein acid phenotype also significantly increased 43 
atazanavir V/F (p<0.05). These in vivo results indicate that atazanavir pharmacokinetics is 44 
moderately influenced by its protein binding, especially to alpha 1 glycoprotein acid without 45 
expected clinical consequences.  46 
47 
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Introduction 48 
Atazanavir is an azapeptide protease inhibitor, with a distinct resistance and tolerance profile 49 
approved for use in combination treatment of HIV-1 in the US and Europe (11, 12, 17). In the 50 
US, one of the recommended antiretroviral regimens is the combination of atazanavir / ritonavir 51 
with tenofovir / emtricitabine. Recommended doses of atazanavir are 400 mg once daily taken 52 
with food without ritonavir in therapy-naive patients or 300 mg in combination with low-dose 53 
ritonavir (100 mg) once daily in antiretroviral-experienced patients, or when combined with 54 
tenofovir (7). The major advantages of atazanavir are its simplicity of administration and a 55 
favourable adverse effects profile, especially on lipid parameters.  56 
Major pharmacokinetic characteristics of atazanavir are a variable absorption through the gut, 57 
86% plasma protein binding on albumin and alpha 1 glycoprotein acid (orosomucoid) and 58 
elimination through biotransformation which involved CYP3A. Although consequences of 59 
CYP3A metabolism on first pass effect and drug-drug interactions have been largely studied, 60 
there is a lack of information on consequences of protein binding on atazanavir pharmacokinetics.  61 
It is now recognized that protein binding is an important modulator of protease inhibitor 62 
disposition and unbound concentration inhibitor is considered as the active moiety which is 63 
available to cross cell membranes. Therefore variations in the concentrations and structures of 64 
orosomucoid and albumin under physiological or pathological infections such as HIV infection 65 
are likely to influence protease inhibitors pharmacokinetics (3). Albumin concentrations could be 66 
significantly reduced in patients with liver disease such as co-infections with hepatitis B virus or 67 
C virus. Orosomucoid, also called alpha 1 glycoprotein acid, is a glycoprotein which is controlled 68 
by a cluster of three adjacent genes : AGP-A which codes for the major protein ORM1; AGP-B 69 
and AGP-B’ which code for the protein ORM2 (14). The proteins ORM1 and ORM2 are 70 
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different by a sequence of 22 amino-acids. The protein ORM1 is polymorphic with three variants: 71 
ORM1*F1, ORM1*S and ORM1*F2, whereas the protein ORM2 is generally monomorphic with 72 
one variant: ORM2*A (8). This polymorphism could be responsible for interindividual variation 73 
in the plasma binding of protease inhibitors, which might influence their pharmacokinetic 74 
parameters.  75 
The purpose of this work was to determine the in vitro binding characteristics of atazanavir. Then 76 
we evaluate whether albumin concentration and/or alpha 1 glycoprotein acid concentration and 77 
alpha 1 glycoprotein acid variants are pertinent covariates in the population pharmacokinetics 78 
analyses of atazanavir used in combination with ritonavir tenofovir in HIV-infected patients 79 
included in a clinical trial (ANRS 107 – Puzzle 2) (22).  80 
Methods 81 
Atazanavir in vitro binding experiments 82 
Alpha 1 glycoprotein acid and serum albumin solutions were prepared in pH 7.4 phosphate-83 
buffered saline. Concentrations of alpha 1 glycoprotein acid and serum albumin used were those 84 
found in normal patients and were 0.7 g/L and 40 g/L respectively. These solutions were spiked 85 
with known amounts of atazanavir to yield the following final concentrations: 0, 500, 1000, 1500, 86 
2000, 5000, 10000, 15000 and 30000 ng/mL. Bound and unbound atazanavir were separated by 87 
ultrafiltration of 500 µL samples using Centrifree devices (Amicon, YM-300 filter system, 88 
Millipore Corp., Bedford, Massachussets, USA) at 3000 g during two hours at 30°C. Atazanavir 89 
was then measured in the ultrafiltrate according to a method developed for amprenavir (1). The 90 
Amicon Centrifree YM-300 filter system (Millipore Corp. Bedford, MA) with a membrane 91 
molecular weight cut off of 30,000 Daltons was used to ultrafiltrate plasma samples. The driving 92 
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force for ultrafiltration was provided by centrifugation (Jouan, GR 4.11) at 2000 g, at 30°C. 93 
Duration of centrifugation was 120 minutes to obtain an ultrafiltrate volume of at least 200 mL 94 
from a 500-mL. Atazanavir concentrations in ultrafiltrate were measured by HPLC with 95 
separation on a C18 column after liquid-liquid extraction and UV detection at 220 nm. The 96 
mobile phase consisted of pH 5.6 phosphate buffer/acetonitrile/methanol (480/110/110, vol/vol) 97 
and the flow rate was 1.1 mL/min. Retention times for atazanavir and 6,7-dimethyl-2,3-di-(2-98 
pyridyl)-quinoxaline (internal standard from Sigma Aldrich Chemicals) were 15 and 30 minutes 99 
respectively in our chromatographic system. 100 
Unbound fraction was the ratio of unbound atazanavir and total atazanavir concentrations. The 101 
graph of the drug bound concentration as a function of the drug unbound concentration depicts 102 
the protein binding system (24).  103 
 104 
Population pharmacokinetic analysis of atazanavir in patients 105 
Study design and population 106 
ANRS 107–Puzzle 2 was a randomised, open-label, multiple-dose trial evaluating the efficacy 107 
and safety of a combination of atazanavir/ritonavir and tenofovir in HIV-infected patients with 108 
multiple antiretroviral treatment failures. The study design is detailed elsewhere (22). From week 109 
3 to week 26, all patients received atazanavir/ritonavir (300 mg / 100 mg QD) plus tenofovir 110 
disoproxil fumarate (300 mg QD equivalent to 245 mg of tenofovir disoproxil or 136 mg of 111 
tenofovir) and nucleoside reverse transcriptase inhibitors (NRTIs) selected according to the 112 
baseline reverse transcriptase genotype of the HIV isolate infecting each patient. Drugs were 113 
administered in the morning with a light continental breakfast. 114 
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Before inclusion, all patients gave their written informed consent. The protocol was approved by 115 
the Institutional Review Board of Saint Antoine Hospital, Paris VI University. HIV-infected 116 
patients were eligible for inclusion if they met the following criteria: documented treatment 117 
failure with at least two PIs and one non-nucleoside reverse transcriptase inhibitor, HIV RNA 118 
>10 000 copies/mL, no change in antiretroviral treatment within the last month before inclusion 119 
in this study, normal liver function.  120 
Plasma collection 121 
Blood samples for biochemical and immuno-virological measurements were drawn at screening 122 
and at regular time intervals after inclusion. Blood samples for atazanavir plasma concentrations 123 
assay were collected prior to drug intake in the morning at week 6, 1 month after starting the full 124 
antiretroviral treatment, atazanavir + ritonavir + tenofovir + optimized background treatment, 125 
according to the design of the ANRS107 study (22). For 10 patients included in the 126 
pharmacokinetic substudy, additional blood samples were collected after dosing at times 1, 2, 3, 127 
5, 8 and 24 hours (23). Plasma samples were kept at –20°C until analysis. The actual times of 128 
drug administration and sampling were recorded. 129 
Drug assays 130 
Atazanavir concentrations were measured in plasma patients samples by validated LC/MS/MS 131 
assays (Bristol-Myers Squibb, Saint Nazaire, France). The lower limits of quantification (LOQ) 132 
were 1 ng/mL. Day-to-day variabilities for the quality control samples were 5.7%.  133 
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Biochemical and virological measurements 134 
Absolute numbers of CD4 lymphocytes, plasma HIV RNA levels, blood chemistry parameters 135 
(albumin, total bilirubin, total cholesterol, triglycerides, alanine and aspartate aminotransferases) 136 
were determined according to standard assays (22).  137 
Determination of alpha 1 glycoprotein acid concentrations and phenotypes 138 
Alpha 1 glycoprotein acid plasma concentrations were measured by nephelemetry (BN Prospec, 139 
Dade Behring). Alpha 1 glycoprotein acid phenotypes (ORM1*S-ORM2*A, ORM1*F1S-140 
ORM2*A and ORM1*F1-ORM2*A) were determined on plasma samples by isoelectric focusing 141 
according to the method developed by Eap and Baumann, with some modifications (10).  142 
Population pharmacokinetic modelling 143 
Data at week 6 were analysed using a population approach with the first-order method 144 
(WinNonMix version 2.0.1, Pharsight Corporation, Mountain View, CA, USA) and 145 
parameterised with the apparent volume of distribution (V/F), the first order absorption rate 146 
constant (ka) and the apparent clearance (Cl/F). The statistical model for the observed plasma 147 
concentrations of the drug Cij in patient i at time tij was given by: Cij = f(tij,θi) + εij where θi is the 148 
pharmacokinetic parameter vector of patient i, εij the residual error and f the pharmacokinetic 149 
model.  150 
An exponential random-effect model was chosen to describe inter-individual variability: θi = θ 151 
exp (ηi) where θ is the population mean vector of the pharmacokinetic parameters and ηi 152 
represents the random effect vector. Random effects were assumed to follow a normal 153 
distribution with zero mean and variance matrix Ω which was supposed to be diagonal. Residual 154 
variability was modelled using a proportional error model.  155 
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Goodness of fit plots (observed versus predicted population and individual concentrations, 156 
weighted residuals versus predicted concentrations and versus time) were examined for each 157 
model. Tested covariates were age, weight, body mass index, creatinine clearance at week 6, 158 
alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) at baseline, plasma 159 
alpha 1 glycoprotein acid and albumin concentrations at week 6, alpha 1 glycoprotein acid 160 
phenotypes, coinfections (hepatitis B infection and/or hepatitis C infection), ritonavir trough and 161 
average concentrations and combined NRTIs,. Continuous variables were centred on their 162 
median. The sex of the patients was not tested as a covariate because there were only two females 163 
in the population. The effects of covariates were tested on each individual parameter (correlation 164 
test for continuous variables and ANOVA for categorical variables) using Statgraphics version 165 
5.1 (Manugistics, Inc. Rockville, Maryland, USA). The covariates that were found to have a 166 
significant effect (p < 0.05) were then evaluated in the population analysis. The effect of a 167 
covariate was assessed by the likelihood ratio test. In the forward inclusion process, a covariate 168 
was retained in the model if there was a decrease greater than 3.84 in the objective function (p < 169 
0.05, 1 degree of freedom) and if there was a decrease in the interindividual variability of the 170 
associated pharmacokinetic parameter. From the best model including covariates, a backward 171 
elimination procedure was then used to test whether all covariates selected should remain in the 172 
final model. When deletion of a covariate (p < 0.05) significantly increased the log-likelihood (> 173 
3.84), that covariate was kept in the model.  174 
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Results 175 
Atazanavir in vitro binding 176 
In a solution of 0.7 g/L of alpha 1 glycoprotein acid, atazanavir was found to bind to one high 177 
affinity saturable site at about 31.1%. The association constant was 4.61 10
5
 L/mol and the 178 
number of sites 0.61. In a solution of 40 g/L of serum albumin, mean unbound fraction of 179 
atazanavir was found to be 21.3% and was constant up to 15000 ng/mL of total atazanavir. This 180 
suggested that atazanavir binds to one low-affinity non-saturable site. The number of sites and the 181 
affinity constant were not differentiated and the product was estimated as 6352 L/mol. When 182 
atazanavir total concentrations were above 15000 ng/mL, atazanavir unbound fraction increase to 183 
30.9%, protein binding sites becoming saturated (figure 1). 184 
Population pharmacokinetic analysis of atazanavir in patients 185 
Patients 186 
Fifty-one patients completed the study at week 6 and ten patients were included in the 187 
pharmacokinetic substudy. The characteristics of these 51 patients are summarised in table 1. The 188 
NRTIs combined with ritonavir-boosted atazanavir plus tenofovir were lamivudine (n=40), 189 
abacavir (n=30), didanosine (n=18), zidovudine (n=15), zalcitabine (n=5) and stavudine (n=2). 190 
Twenty-three patients were hepatitis virus B and/or C co-infected.  191 
 192 
Alpha 1 glycoprotein acid concentrations and phenotypes 193 
Alpha 1 glycoprotein acid concentrations were 1.0 g/L (0.6-1.5) at week 6 and were elevated in 194 
15 patients (28.8%) accounting for their age and sex.  195 
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Five patients had the phenotype ORM1*S-ORM2*A, 19 ORM1*F1-ORM2*A and 28 were 196 
heterozygous and presented ORM1*F1S-ORM2*A. The allele ORM1*F2 was not observed in 197 
this rather small sample. The allele ORM2*A was monomorphic and observed in all sera of 198 
patients. The ORM1 allele frequencies were as follows: 0.635 for ORM1*F1 and 0.365 for 199 
OMR1*S. Good agreement was found between observed and expected values, assuming a Hardy-200 
Weinberg equilibrium (p > 0.5). Total plasma concentrations of alpha 1 glycoprotein acid were 201 
not found to be significantly dependant on alpha 1 glycoprotein acid phenotypes.  202 
Atazanavir model 203 
Basic model 204 
A one-compartment model with first-order absorption and elimination was used to describe 205 
atazanavir pharmacokinetics. The population parameter estimates, their relative standard error of 206 
estimation (RSE %) and their inter-individual variability for this basic model are shown in table 207 
2.  208 
Covariates model building 209 
From this basic model, we tested the effects of the covariates on the individual estimates of the 210 
random effects. Using the estimated individual parameters, significant effects of hepatitis B 211 
and/or C infection on ka (p = 0.030), of plasma alpha 1 glycoprotein acid concentration, 212 
didanosine, ALAT level, ASAT level, ritonavir trough and average concentrations on Cl/F (p = 213 
0.001 ; 0.028 ; 0.037 ; 0.017 ; 0.009 ; 0.006 respectively) and of plasma alpha 1 glycoprotein acid 214 
concentration, ORM1*S alpha 1 glycoprotein acid phenotype on V/F (p = 0.009; 0.008 215 
respectively) were found.  216 
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According to the likelihood ratio test, the final population model had plasma alpha 1 glycoprotein 217 
acid concentration (AAG), ALAT level effects on Cl/F (p < 0.01 ; p <0.01 respectively) and 218 
ORM1*S alpha 1 glycoprotein acid phenotype (ORM1*S) effects on V/F (p < 0.05). The 219 
equations are:  220 
Cl/Fi = (Cl/F - 
ALAT
CL/F (ALATi/29)- 
AAG
CL/F (AAG/1.0)) x exp(Cl/Fi) 221 
 where 29 (IU/L) and 1.0 (g/L) are the median ALAT and AAG levels. 222 
V/Fi = (V/F  
ORM1*S
V/F) x exp(V/Fi) 223 
The population parameters of this final model and their relative standard errors of estimation are 224 
given in table 2. The goodness of fit plots (not shown) were all very satisfactory for the basic and 225 
final models. 226 
The apparent volume of distribution was estimated to be 79.7 L and increased about 2-fold in 227 
patients with the ORM1*S phenotype. Absorption rate constant was estimated to be 0.73 /h. The 228 
apparent clearance was estimated to be 8.1 L/h when ALAT was 29 IU/L and alpha 1 229 
glycoprotein acid level was 1.0 g/L. Median (range) half-life was 6.9 h (4.0-18.2). We found an 230 
increase of 34% in mean atazanavir area under the curve (AUC, 47410 ng.h/mL versus 35432 231 
ng.h/mL, p=0.0004) and of 12% in mean half-life (7.8 h versus 6.9 h, p=0.03) in patients who had 232 
an elevated ALAT level ( 40 IU/L), compared with patients with a normal ALAT level. A 36% 233 
increase in mean atazanavir AUC (49644 ng.h/mL versus 36529 ng.h/mL) and a 28% increase in 234 
mean half-life (9 h versus 7 h) were observed in patients with elevated alpha 1 glycoprotein acid 235 
(according to their age and sex), compared with those with a normal alpha 1 glycoprotein acid 236 
level. 237 
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The inter-individual variabilities of absorption rate constant, apparent volume of distribution and 238 
apparent clearance were 139.3%, 27.0% and 26.7%, respectively. They were slightly decreased 239 
from the basic model by the incorporation of the covariates. Residual variability was 19.9%.  240 
Figure 2 shows the model-predicted concentrations and the observed concentrations versus time 241 
when ALAT and plasma alpha 1 glycoprotein acid concentrations were 29 IU/L and 1.0 g/L, 242 
respectively, in patients with or without the alpha 1 glycoprotein acid ORM1*S phenotype. 243 
Discussion  244 
Atazanavir is a potent and safe HIV PI with a pharmacokinetic profile that allows once daily oral 245 
administration and which can be optimised by adding low-dose ritonavir. All patients included in 246 
this study received ritonavir boosted atazanavir and a relationship was found between atazanavir 247 
clearance and ritonavir concentrations. However variation in ritonavir concentrations was not 248 
found to impact atazanavir pharmacokinetics to a significant extent and therefore was not retain 249 
in the final model.  It is known that protein binding affect PI disposition (3) and could reduce the 250 
antiviral effect of these drugs (13). It was reported that atazanavir binds to both alpha 1 251 
glycoprotein acid and albumin to a similar extent, but binding parameters were unknown (12). 252 
Our in vitro data demonstrate that atazanavir has a higher affinity to alpha 1 glycoprotein acid 253 
than to albumin. However, alpha 1 glycoprotein acid is present at about 1/40 the concentration of 254 
albumin in plasma. Consequently, the binding of atazanavir to alpha 1 glycoprotein acid was 255 
saturable above 6000 ng/mL whereas the saturation of albumin appears above 15000 ng/mL of 256 
atazanavir. A similar result was already found for saquinavir (15). As for many basic drugs, alpha 257 
1 glycoprotein acid has a high affinity but albumin has a higher capacity for binding (16). In 258 
patients treated by atazanavir/ritonavir at the recommended daily dose of 300/100 mg, trough 259 
plasma atazanavir concentrations are around 1000 ng/mL. Consequently, alpha 1 glycoprotein 260 
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acid is the major protein involved in atazanavir binding. These findings are essential because 261 
alpha 1 glycoprotein acid concentration can vary considerably as a result of disturbances of 262 
homeostasis. It increases during acute or chronic inflammation and infectious disease. HIV-263 
infected patients are therefore likely to exhibit increased concentrations of alpha 1 glycoprotein 264 
acid (3, 16, 21). Moreover the alpha 1 glycoprotein acid polymorphism could be responsible for 265 
interindividual variation in the plasma binding of protease inhibitors, which might influence their 266 
disposition.  267 
The impact of proteins that bind atazanavir on atazanavir pharmacokinetics was evaluated in 51 268 
HIV infected patients having failed several lines of previous antiretroviral treatment and included 269 
in the ANRS 107-Puzzle 2 trial. Unfortunately, atazanavir unbound fraction could not be 270 
measured in these patients as remaining samples volumes was too low 271 
This is the first population model analysis to explore the possible influence of alpha 1 272 
glycoprotein acid concentrations, alpha 1 glycoprotein acid phenotypes, albumin concentrations, 273 
ALAT and ASAT levels and/or hepatitis B and C coinfections on atazanavir pharmacokinetic 274 
parameters.  275 
In this very advanced population, alpha 1 glycoprotein acid concentrations remained elevated in 276 
29% of the patients even though they had received a new treatment for 6 weeks. This could be 277 
explained by the weak virological response to the new treatment and the lack of effect of the 278 
antiretroviral treatment on the inflammation due to HIV infection (22). The relative frequencies 279 
of alpha 1 glycoprotein acid phenotypes found here are close to those previously described in 280 
healthy subjects or in HIV-infected patients (5, 8). We did not find ORM1*F2 on this population 281 
but this variant is present only at a low allelic frequency (9, 19). As already described in healthy 282 
subjects, alpha 1 glycoprotein acid plasma concentrations were not found to differ between the 3 283 
phenotypes (18). 284 
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To determine atazanavir pharmacokinetic parameters and the influence of protein binding, we 285 
used a population approach because only ten patients had a complete pharmacokinetic profile. 286 
The pharmacokinetics of atazanavir was described by a one-compartment model with first-order 287 
absorption and first-order elimination with random effects on ka, V/F and Cl/F. This structural 288 
model was similar to that of Dailly et al. and Colombo et al., although Colombo et al. described a 289 
first-order absorption with a lag time (4, 6). Our estimation of atazanavir pharmacokinetic 290 
parameters, apparent volume of distribution, absorption rate constant, apparent clearance and 291 
half-life are in the same range as those of previous studies (4, 6, 17, 23). The atazanavir apparent 292 
clearance of 9.8 L/h demonstrates that atazanavir has low extraction ratio with clearance 293 
depending on the unbound fraction and intrinsic clearance. The atazanavir apparent volume of 294 
distribution of 78 L (1.2 L/kg) indicates that plasma protein binding is not a restricting factor to 295 
body distribution. Assuming that pharmacologic effect is related to exposure to unbound drug 296 
concentrations (AUCu), which after oral administration, depends on the fraction absorbed 297 
through the gut wall, the dose and the intrinsic clearance as demonstrated by Benet and Hoener 298 
(2), any change in total drug concentrations should not have clinical consequences. Large inter-299 
individual variability was found for ka (139.3%) as variable absorption of PIs has already been 300 
described.  301 
We found that the apparent clearance of atazanavir decreases with increasing plasma alpha 1 302 
glycoprotein acid concentration. A similar effect was previously reported for lopinavir and 303 
indinavir clearance (5). This result suggests that elevated alpha 1 glycoprotein acid 304 
concentrations could decrease the protein unbound fraction of atazanavir, leading to increased 305 
total atazanavir concentrations, but without change in unbound atazanavir concentrations linked 306 
to drug efficacy (2).  307 
 15 
Interestingly, we found that atazanavir apparent volume of distribution decreases with increased 308 
with alpha 1 glycoprotein acid concentrations and increases with the ORM1*S phenotype. This 309 
suggests that atazanavir may preferentially bind to the ORM1*F1 variant, compared with the 310 
ORM1*S variant. Unfortunately, this hypothesis could not be tested in vitro as human plasma 311 
samples tested for alpha 1 glycoprotein acid variants were not available. In contrast, it was 312 
suggested that lopinavir and indinavir may preferentially bind to the ORM1*S variant (5). There 313 
are conflicting data on preferential binding of neutral and basic drugs such as quinidine to 314 
ORM1*S and ORM1*F1 (18, 20). In vitro drug-binding studies are warranted to determine the 315 
possible different capacities of the ORM1 variants. 316 
Overall, increases in alpha 1 glycoprotein acid lead to a modest 28% increase in atazanavir half 317 
life which should not have any clinical consequence, but could contribute to  the interindividual 318 
variability of atazanavir pharmacokinetics although to a lesser extend than absorption or CYP3A 319 
activity.  320 
We found that the apparent clearance of atazanavir decreases with increasing ALAT. This was 321 
expected as atazanavir, like other PIs, is extensively metabolised by hepatic CYP3A isoenzymes, 322 
which are decreased in patients with liver failure and directly affect the intrinsic clearance. 323 
However, such a relationship is remarkable as liver dysfunction was mild to moderate in our 324 
patients. A 42% increase in AUC and longer terminal half-life (12 versus 6 hours) have been 325 
reported in volunteers with hepatic impairment (Child-Pugh grade B or C), compared with 326 
healthy volunteers (12). In the present study, we found a similar increase in atazanavir AUC and 327 
half-life in patients who had an elevated ALAT level. Our data, although limited, could suggest 328 
that high atazanavir concentrations are expected with severe liver dysfunction. As previously 329 
described, age, body weight and body mass index did not influence atazanavir pharmacokinetics 330 
(4). Most of our patients were males, so no influence of sex on atazanavir pharmacokinetics could 331 
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be detected. In keeping with our in vitro data, atazanavir pharmacokinetics was not influenced by 332 
albumin concentrations; however in these patients, there was a small variability in albumin 333 
concentrations. 334 
 335 
In conclusion, this study demonstrates that atazanavir pharmacokinetics is modestly influenced 336 
by its protein binding, especially to alpha 1 glycoprotein acid. The effect of alpha 1 glycoprotein 337 
acid concentrations or polymorphisms or liver enzyme elevations on the unbound moiety able to 338 
cross biologic membranes and exert a pharmacologic effect is unknown as is therefore, the 339 
potential clinical significance, and that this is a limitation of this work. 340 
 341 
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 Figures legends 431 
Figure 1: Bound atazanavir concentrations versus unbound atazanavir concentrations in solutions 432 
of orosomucoid (solid circles) and albumin (open circles). The curve is an ordinary least-square 433 
fit of the Emax model to the data using WinNonLin. 434 
 435 
Figure 2: Observed atazanavir concentrations (solid circles in patients with the ORM1*S 436 
phenotype and open circles in patients without the ORM1*S phenotype) and predicted population 437 
concentrations for median ALAT (29 IU/L) and median orosomucoid (1.0 g/L) in patients with 438 
(continuous line) or without (dashed line) the ORM1*S phenotype versus time, at week 6.439 
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Tables 440 
 441 
Table 1: Characteristics of the 51 patients included in the population pharmacokinetic analysis 442 
 443 
 Median min-max 
Age (years) 41 29-62 
Week 6 weight (kg) 65.6 45.0-105.6 
Week 6 body mass index (kg/m
2
) 21.3 17.0-33.6 
Baseline ALAT level (IU/L) 29 5-114 
Baseline ASAT level (IU/L) 29 16-149 
Week 6 ALAT (IU/L) 38 7-175 
Week 6 creatinine clearance (mL/min) 87 23-178 
Week 6 albumin (g/L) 40.4 31.2-47.7 
Week 6 orosomucoid (g/L) 1.0 0.6-1.5 
ALAT: alanine aminotransferase 444 
ASAT: aspartate aminotransferase 445 
446 
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Table 2: Population pharmacokinetic parameters of atazanavir (estimates and relative standard 447 
errors of estimation) for the basic model and for the final model 448 
 449 
 Basic model Final model 
Parameters Estimate RSE (%) Estimate RSE (%) 
ka (h
-1
) 0.75 7.6 0.73 10.7 
Cl/F (L/h) 7.8 9.0 13.3 13.2 
ALATCl/F - - 0.86 35.0 
AAGCl/F - - 4.3 46.9 
V/F (L) 78.2 10.5 79.7 10.5 
ORM1*SV/F - - 1.9 32.8 
ka (%) 138.7 21.0
a
 139.3 26.2
a
 
Cl/F (%) 43.4 54.4
a
 26.7 27.8
a
 
V/F (%) 31.1 64.8
a
 27.0 102.2
a
 
 (%) 18.3 37.2a 19.9 50.3a 
a
 RSE for 2ka, 
2
V/F, 
2
Cl/F and 
2 
450 
ka: absorption rate constant, Cl/F: apparent clearance, V/F: apparent volume of distribution 451 
ALATCl/F: facteur associated with ALAT concentrations on atazanavir Cl/F 452 
AAGCl/F: facteur associated with AAG concentrations on atazanavir CL/F
 
453 
ORM1*SV/F: facteur associated with ORM1*S phenotype on atazanavir V/F 454 
ka, Cl/F, V/F: inter individual variabilities for ka, Cl/F and V/F respectively 455 
: residual error 456 
 457 
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